Effect of rivaroxaban on venous thromboembolism after posterior lumbar interbody fusion in elderly patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-17012975

Enrollment

Unknown

Registered

2017-10-13

Start date

2015-01-01

Completion date

Unknown

Last updated

2017-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Venous thromboembolism

Interventions

Rivaroxaban: Rivaroxaban

placebo:placebo

Eligibility

Sex/Gender

All

Age

60 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged 60 years and more; 2. Patients who required posterior lumbar interbody fusion (PLIF) therapy; 3. Patients diagnosed with negative DVT in lower limbs by preoperative color duplex Doppler ultrasound (CDDU); 4. Patients must be informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with a history of VTE or spinal surgery; 2. Patients with active bleeding or a high risk of bleeding (prothrombin activity platelet < 60%, 100 × 109 L-1); 3. Patients with poor tolerance for rivaroxaban; 4. Patients with severe osteoporosis; 5. Warfarin administration history; 6. Patients who were lost follow-up during the test.

Design outcomes

Primary

Measure	Time frame
Wells score;the ratio of venous thromboembolism;	—

Secondary

Measure	Time frame
the ratio bleeding event;	—

Countries

China

Contacts

Public ContactXiaofeng Chen

Department of Othopaedics, Guangzhou Panyu Hospital of Chinese Medicine

cxf1159@163.com+86 18138743312

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026